{"tid":2518289,"cid":5,"subCid":10,"title":"世衛專家︰對科興及國藥疫苗安全數據信心低 副作用數據不足","createTime":"2021-05-06T02:18:50.000Z","updateTime":"2021-05-06T02:48:06.000Z","uid":21470,"like":2,"dislike":0,"uniUserReply":3,"replies":[{"pid":"ac6deb264f5ed07b28f8307231ae36750d8031af","tid":2518289,"uid":21470,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-05-06T02:18:50.000Z","msg":"世衛專家︰對科興及國藥疫苗安全數據信心低<br />\n<br />\n世衛正審視兩款中國新冠疫苗，預料最快本周決定是否批准緊急使用。世衛的免疫戰略諮詢專家組普遍認為中國疫苗有效，但關注安全性方面的數據不足。報告指科興疫苗對60歲以下人士有效，但欠缺嚴重副作用的數據；對於59歲以下人士接種後出現嚴重副作用風險的數據，專家組的信心為中等；對60歲以上人士的風險數據信心則為低。<br />\n<br />\n至於國藥疫苗，報告指第三階段試驗結果顯示，接種兩劑後有效率為78.1%，輕微低於早前官方公布的79.34%。專家組指有信心疫苗對成年人有保護效用，但對於60歲或以上人士接種風險的數據信心則「非常低」。<br />\n<br />\n世衛發言人表示，會審視不同資料和數據決定是否批准緊急使用中國的新冠疫苗，包括專家組的報告。<br />\n<br />\n原文網址：<a href=\"https://www.881903.com/news/international/2390355\" data-sr-url=\"https://r.lihkg.com/link?u=https%3A%2F%2Fwww.881903.com%2Fnews%2Finternational%2F2390355&d=lnSleIYCVJUMUgC9CFuHQgjGR3CVFSgRSSfEWrWQqBA%3D&h=7a656fd5\" data-auto-link target=\"_blank\">https://www.881903.com/news/international/2390355</a>"},{"pid":"d37a83c37e2bc7e4eb50c34dd793e7e47455a65f","tid":2518289,"uid":4964,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-05-06T02:25:49.000Z","msg":"小罵大幫忙？"},{"pid":"980d595a4d1d7060dfd4671f29a24113f5eda421","tid":2518289,"uid":160592,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2021-05-06T02:48:06.000Z","msg":"@三民主義"}]}